重症患者连续性肾脏替代治疗中的抗凝选择:随机对照试验的系统评价与网状Meta分析
该系统评价与网状Meta分析纳入37项随机对照试验(38篇文章)、2648例参与者、14种比较,评估重症急性肾损伤患者CRRT中不同抗凝方案对滤器寿命、全因死亡率、住院时间、CRRT时长、肾功能恢复、不良事件和费用的影响。与普通肝素相比,区域枸橼酸抗凝更有效延长滤器寿命(MD 12.0,95%CI 3.8至20.2)并降低出血风险。区域普通肝素联合前列环素I2在延长滤器寿命方面似乎优于区域枸橼酸抗凝(MD 37.0,95%CI 12.0至62.0)、低分子肝素(MD 41.3,95%CI 15.6至67.0)及其他评估的抗凝方案,但仅有一项46例参与者的随机对照试验评估该方案。大多数评估的抗凝方案在ICU住院时间、全因死亡率、CRRT时长、肾功能恢复和不良事件方面无统计学显著差异。
要点
- 与普通肝素相比,区域枸橼酸抗凝延长滤器寿命(MD 12.0,95%CI 3.8至20.2)并降低出血风险。
- 区域普通肝素联合前列环素I2延长滤器寿命似乎优于区域枸橼酸抗凝(MD 37.0,95%CI 12.0至62.0)和低分子肝素(MD 41.3,95%CI 15.6至67.0)。
- 区域普通肝素联合前列环素I2仅有一项46例参与者的随机对照试验评估,作者认为在推荐该方案前需要更多高质量研究。
- 大多数抗凝方案在ICU住院时间、全因死亡率、CRRT时长、肾功能恢复和不良事件方面无统计学显著差异。
适用人群与场景
- 重症急性肾损伤接受连续性肾脏替代治疗的患者。
研究设计与关键结果
- 系统评价与网状Meta分析纳入37项随机对照试验(38篇文章),共2648例参与者,14种比较。
- 普通肝素和区域枸橼酸抗凝是最常用的抗凝剂。
- 与普通肝素相比,区域枸橼酸抗凝延长滤器寿命(MD 12.0,95%CI 3.8至20.2)并降低出血风险。
- 区域普通肝素联合前列环素I2延长滤器寿命似乎优于区域枸橼酸抗凝(MD 37.0,95%CI 12.0至62.0)、低分子肝素(MD 41.3,95%CI 15.6至67.0)及其他评估的抗凝方案。
- 仅有一项纳入的随机对照试验(46例参与者)评估了区域普通肝素联合前列环素I2。
- 大多数评估的抗凝方案在ICU住院时间、全因死亡率、CRRT时长、肾功能恢复和不良事件方面无统计学显著差异。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与网状Meta分析。
- 局限:区域普通肝素联合前列环素I2的SUCRA分析和森林图受限,因仅纳入一项研究。
- 局限:作者认为在推荐区域普通肝素联合前列环素I2前需要更多高质量研究。
- 局限:需要进一步更大规模的高质量随机对照试验来加强关于最佳抗凝选择以降低全因死亡率和不良事件、促进肾功能恢复的证据。
对床旁实践的改变
- 与普通肝素相比,区域枸橼酸抗凝是重症需要CRRT患者的首选抗凝剂。
- 作者认为在推荐区域普通肝素联合前列环素I2前需要更多高质量研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Continuous renal replacement therapy (CRRT) is a widely used standard therapy for critically ill patients with acute kidney injury (AKI). Despite its effectiveness, treatment is often interrupted due to clot formation in the extracorporeal circuits. Anticoagulation is a crucial strategy for preventing extracorporeal circuit clotting during CRRT. While various anticoagulation options are available, there were still no studies synthetically comparing the efficacy and safety of these anticoagulation options.
METHODS: Electronic databases (PubMed, Embase, Web of Science, and the Cochrane database) were searched from inception to October 31, 2022. All randomized controlled trials (RCTs) that examined the following outcomes were included: filter lifespan, all-cause mortality, length of stay, duration of CRRT, recovery of kidney function, adverse events and costs.
RESULTS: Thirty-seven RCTs from 38 articles, comprising 2648 participants with 14 comparisons, were included in this network meta-analysis (NMA). Unfractionated heparin (UFH) and regional citrate anticoagulation (RCA) are the most frequently used anticoagulants. Compared to UFH, RCA was found to be more effective in prolonging filter lifespan (MD 12.0, 95% CI 3.8 to 20.2) and reducing the risk of bleeding. Regional-UFH plus Prostaglandin I2 (Regional-UFH + PGI2) appeared to outperform RCA (MD 37.0, 95% CI 12.0 to 62.0), LMWH (MD 41.3, 95% CI 15.6 to 67.0), and other evaluated anticoagulation options in prolonging filter lifespan. However, only a single included RCT with 46 participants had evaluated Regional-UFH + PGI2. No statistically significant difference was observed in terms of length of ICU stay, all-cause mortality, duration of CRRT, recovery of kidney function, and adverse events among most evaluated anticoagulation options.
CONCLUSIONS: Compared to UFH, RCA is the preferred anticoagulant for critically ill patients requiring CRRT. The SUCRA analysis and forest plot of Regional-UFH + PGI2 are limited, as only a single study was included. Additional high-quality studies are necessary before any recommendation of Regional-UFH + PGI2. Further larger high-quality RCTs are desirable to strengthen the evidence on the best choice of anticoagulation options to reduce all-cause mortality and adverse events and promote the recovery of kidney function. Trial registration The protocol of this network meta-analysis was registered on PROSPERO ( CRD42022360263 ). Registered 26 September 2022.
参考来源
- Zhou Z, Liu C, Yang Y, et al. Anticoagulation options for continuous renal replacement therapy in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Crit Care. 2023. PMID: 37287084. doi:10.1186/s13054-023-04519-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。